Skip to main content
. Author manuscript; available in PMC: 2010 Jan 19.
Published in final edited form as: BJU Int. 2009 Jul 8;105(2):185–190. doi: 10.1111/j.1464-410X.2009.08698.x

TABLE 4.

Literature review of prospective randomized trials on biochemical recurrence free rates in patients treated with and without 3 months of neoadjuvant hormone therapy before radical prostatectomy

References N Clinical Stage Followup (months) % BCR-free in RP only group % BCR-free in NHT and RP group Significant
Fair[8] 137 cT1-3 35 NR NR No
Schulman[9] 402 cT2-3 48 67 74 No
Aus[7] 126 cT1b-T3a 82 52 50 No
Soloway[10] 282 cT2b 60 68 65 No
Klotz[19] 213 cT1-2 72 66 62 No*
*

Improved biochemical recurrence in highest risk PSA group (PSA > 20 ng/mL).

RP, radical prostatectomy; NHT, neoadjuvant hormone therapy; NR, not recorded; PSA, prostate specific antigen